-
Chongqing Zhifei Acquires 51% Stake in Chenan Bio for RMB593 Million
•
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), the distribution partner for US giant Merck’s Gardasil in China, has announced the acquisition of a 51% stake in compatriot firm Chongqing Chenan Biopharmaceutical Co., Ltd. for RMB 593 million (USD 82 million). This strategic move aims to expand Zhifei’s presence in the…
-
Chongqing Zhifei Biological and GlaxoSmithKline Amend Distribution Agreement for Herpes Vaccine
•
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a supplementary exclusive distribution and co-promotion agreement with UK pharmaceutical major GlaxoSmithKline (GSK, NYSE: GSK), optimizing and adjusting the original deal concerning the recombinant herpes zoster vaccine. The revised agreement removes the original minimum procurement amount, allowing Zhifei Bio…
-
Chongqing Zhifei Biological’s Influenza Vaccine Application Accepted by China’s Drug Evaluation Center
•
On October 24, 2024, the Center for Drug Evaluation of the National Medical Products Administration indicated that the influenza virus split vaccine marketing application from Chongqing Zhifei Biological Products Co., Ltd. (SHE: 300122)’s wholly-owned subsidiary, Zhifei Longkoma, has been accepted, with the acceptance number CXSS2400114. Currently, Chongqing Zhifei Biological has…
-
Chongqing Zhifei Biological’s EC Injection Receives Market Approval in Indonesia
•
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a leading biopharmaceutical company based in China, has announced that it has received market approval in Indonesia for its in-house developed Category 1 drug, the recombinant Mycobacterium tuberculosis fusion protein (EC) injection. This development marks an important milestone for the company as it…
-
Chongqing Zhifei Biological Reports 38.3% YOY Revenue Growth in 2023 Financial Results
•
Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a biopharmaceutical company based in China, has released its financial report for 2023, recording revenues of RMB 52.918 billion (USD 7.3 billion), an increase of 38.3% year-on-year (YOY). Net profits for the company were reported at RMB 8.07 billion (USD 1.11 billion), marking…
-
GSK Posts 5% YOY Growth in 2023 Financials, Vaccines Business Drives Expansion
•
GSK plc (NYSE: GSK), the UK pharmaceutical giant, announced its financial results for the fourth quarter and full-year 2023, with a 5% year-on-year (YOY) growth to GBP 30.3 billion (USD 38.5 billion) in revenue over the 12-month period. When excluding the impact of COVID-related products, the company’s sales surged by…
-
GSK’s CCO Calls China a Hotbed for Innovative Molecules and Licensing Deals
•
In an interview with the Financial Times, Luke Miels, Chief Commercial Officer of UK-based GlaxoSmithKline (GSK; NYSE: GSK), highlighted China as a key source of innovative molecules for licensing agreements. Miels attributes this trend to China’s robust chemistry capabilities and the willingness of local companies to out-license their rights: “You…
-
GSK Reports Modest 2% YOY Growth in Q3 2023 Finances, Vaccines Unit Soars 24%
•
UK-based pharmaceutical giant GlaxoSmithKline (GSK; NYSE: GSK) has released its financial report for the third quarter of 2023, showing mixed results over the first three quarters. The company experienced a modest 2% year-on-year (YOY) expansion, reaching GBP 22.3 billion (USD 27.7 billion) at constant exchange rates. Vaccines Unit and General…
-
Chongqing Zhifei Partners with GSK for Shingrix Distribution in China
•
China-based Chongqing Zhifei Biological Co., Ltd. (SHE: 300122) has entered into a sole distribution and co-promotion agreement with UK pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) for its shingles vaccine, Shingrix (recombinant zoster vaccine; RZV). This partnership marks a significant step in enhancing the availability of Shingrix in the Chinese market.…
-
Chongqing Zhifei Biological Partners with PT Bio Farma for Global Tuberculosis Vaccine Development
•
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has entered into a global cooperation memorandum of understanding (MoU) with Indonesia-headquartered PT Bio Farma, focusing on the development of a novel tuberculosis vaccine. This strategic partnership aims to leverage both companies’ expertise to address the pressing global health challenge of tuberculosis.…
-
Chongqing Zhifei Biological Launches Phase I Clinical Trial for Group B Meningococcal Vaccine
•
Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the commencement of a Phase I clinical study for its recombinant Group B meningococcal vaccine (Escherichia coli), marking a significant step in assessing the vaccine’s safety, tolerability, and preliminary immunogenicity. This product is the first of its kind to enter clinical…
-
Zhifei Renews Vaccine Supply Agreement with Merck Sharp & Dohme
•
China-based Chongqing Zhifei Biological Co., Ltd (SHE: 300122) has announced the renewal of a supply, distribution, and co-promotion agreement with Merck Sharp & Dohme (MSD, NYSE: MRK) for the US firm’s vaccine products. Under the renewed agreement, Zhifei aims to secure the supply of MSD’s human papillomavirus (HPV) and pentavalent…
-
Zhifei Biological Products’ BCG Vaccine Filing Accepted by China’s NMPA
•
China-based Chongqing Zhifei Biological Products Co., Ltd (SHE: 300122) has announced that its clinical trial filing for an in-house developed therapeutic BCG vaccine has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step in the development of a new treatment option for bladder…
-
Beijing Luzhu Biotechnology Secures Series C Funding for Meningococcal Vaccine Development
•
China-based Beijing Luzhu Biotechnology Co., Ltd has reportedly secured an undisclosed amount in a Series C (crossover) financing round led by Huapu Haihe Biomedical Fund, Yizhuang Biomedical Fund, and CNCB (Beijing) Equity Investment Fund. This latest funding follows previous rounds including RMB 350 million (USD 52.3 million) in Series B…
